HONG KONG SAR - Media OutReach Newswire - 30 July 2025 - The Greater Bay Area International Clinical Trial Institute of Hong ...

On this first week of clinical rotations as a medical student, my fears surrounding evaluation were nothing short of ...

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic ...

Discover how remote clinical trials and apps like Chloe are transforming health research. Learn how you can participate in ...

The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

A $6 million pre-paid advance agreement, with an initial $1 million advance funded at signing.A $15 million standby equity ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...

Genethon gets UK MHRA nod to initiate pivotal phase 3 trial of GNT0004, a low-dose microdystrophin gene therapy for Duchenne muscular dystrophy: Paris, France Wednesday, July 30, ...